Department of otorhinolaryngology, Ghent University Hospital, Ghent, Belgium.
Curr Pharm Des. 2012;18(16):2336-46. doi: 10.2174/138161212800166022.
Chronic Rhinosinusitis (CRS), a chronic upper airway inflammation, is an inflammation of the nose and the paranasal cavities and is highly prevalent. Chronic rhinosinusitis is currently classified as CRS with nasal polyps or CRS without nasal polyps. This review highlights the pathophysiological differences in CRS on remodeling and on T-cell patterns. Nasal polyps have a high co-morbidity with the lower airway inflammatory disease, asthma. Evidence is accumulating for the role of superantigens, Staphylococcus aureus enterotoxins, in CRS with nasal polyps and asthma, both T helper 2 -biased diseases. Until today there are no biomarkers involved in the diagnosis of CRS or the treatment follow-up. Further differentiation of the phenotype of the disease is needed, which will reflect in the development of new biomarkers and in new innovative treatment options. Defining and predicting response to therapy in individual CRS patients is a challenge for future research.
慢性鼻-鼻窦炎(CRS)是一种慢性上呼吸道炎症,是鼻腔和鼻窦的炎症,其发病率很高。慢性鼻-鼻窦炎目前分为伴有鼻息肉的慢性鼻-鼻窦炎或不伴有鼻息肉的慢性鼻-鼻窦炎。本综述强调了 CRS 在重塑和 T 细胞模式方面的病理生理学差异。鼻息肉与下呼吸道炎症性疾病哮喘的合并发病率很高。超抗原、金黄色葡萄球菌肠毒素在伴有鼻息肉和哮喘的 CRS 中的作用证据正在不断增加,这两种疾病均为 T 辅助细胞 2 型偏向性疾病。直到今天,还没有涉及 CRS 诊断或治疗随访的生物标志物。需要进一步区分疾病的表型,这将反映在新的生物标志物和新的创新治疗方案的发展中。确定和预测个体 CRS 患者对治疗的反应是未来研究的一个挑战。